Oncolytics Biotech's experimental drug Reolysin, in combination with carboplatin and paclitaxel, was associated with the shrinking of tumors in 95% of patients with metastatic or recurrent squamous cell carcinoma of the lung during a Phase II trial. "Based on these findings we intend to continue to look at Reolysin as a treatment for cancers of the lung and cancers that metastasize to the lung," CEO Brad Thompson said.

Full Story:

Related Summaries